Remember to sign in for April 25th DNA DAY!
Join Terri Conneran in conversation with Dr. Collin Blakely and Danielle Hicks while they discuss why biomarker testing is so critical when diagnosing and treating Non Small Cell Lung Cancer.
RSVP ow.ly/Ic2g50RmuJb

Just came in! Video from AACR updates with Dr. Ferdinandos Skoulidis!
If you weren't able to participate for the webinar or you just missed something out, you can re (or watch it) at this link ow.ly/2m9z50RlPBl

NCT06072781 RAMP301
Great points!
🔻
▪︎LGSOC vs. HGSOC distinction
▪︎RAS-MAPK Pathway, cancer biology
▪︎The crossover rationale 📢
▪︎MEKi resensitization with FAKi
▪︎KRASm/ WT ➡️ treatment available to all-comers
▪︎Safety profile
▪︎Asia, Europe, Australia, 🇺🇸

A candid discussion on partnering with patient advocates from TerriConneran and KRASKickers - connect with these groups, empower patients. We’re in this together! #TexasLung24

#ScienceSaturday

Combination #immunotherapy with anti-PD1 and anti-CTLA4 can be potent against some cancers, but can also result in severe toxicities including colitis. To address this, Xue et al screened 3,000 U.S. FDA approved agents and found that the antibacterial drug…

Having fun and learning at the #TexasLung24 with Sandip Patel MD, Brendon Stiles, Dr. Luis E. Raez, Stephen V Liu, MD, TerriConneran, Xiuning Le MD PhD, Dr Tina Cascone, Kami Schnautz and Jason Porter
Can't wait to share more about the conference later!

Having fun and learning at the #TexasLung24 with Sandip Patel MD, Brendon Stiles, Dr. Luis E. Raez, Stephen V Liu, MD, TerriConneran, Xiuning Le MD PhD, Dr Tina Cascone, Kami Schnautz and Jason Porter
Can't wait to share more about the conference later!

This April 25th, let's meet at the GO2 Lung Cancer Youtube Live for DNA DAY!

Join Terri Conneran, Dr. Collin Blakely and Danielle Hicks while they discuss why biomarker testing is so critical when diagnosing and treating NSCLC and SCLC.

RSVP: ow.ly/V7Ep50RjsRA

If your program or any you know of is looking for a determined and compassionate PGY-2, I would be delighted to get in touch and forward my credentials. Any opportunities, leads, or advice are greatly appreciated. Thank you!
#MedTwitter #InternalMedicine #IMResident #Residency

FAK inhibition combined with the RAF/MEK clamp avutometinib overcomes resistance to BRAF and MEK inhibitors and to immune checkpoint blockade in 🎯 BRAFV600E mutant cutaneous melanoma. #AACR24
🔻
verastem.com/wp-content/upl…

RMC-6236 achieved the impossible. A COMPLETE RESPONSE in a heavily pretreated PDAC patient w liver and peritoneal mets Cancer Discovery
Excited lab members Grace Goodhart Amber Amparo could contribute to the nature papers leading up to this
KenOliveLab Syed A. Ahmad KRASKickers

Well #AACR2024 looks promising!!
Do you believe in signs ?
#cancer #research

Congratulations so deserved!!

Cont.

3 / 4

📌 Ras pathway 📌

📌 Others 📌

🔈 End….🙇

Cont.

3 / 4

📌 fusions 📌

📌 Ras pathway 📌

🌟 Updated Oncology Drug List, Ver.2 🌟

💥 Lung - NSCLC & Solid tumors 💥

🧬 Oncogene-driven Target Therapies 🧬

1 / 4

📌 EGFR 📌

👏 Great news! It’s now +12 months in response after experiencing a Lazarus effect. #SCLC needs to be genotyped in people with low smoking exposure. 🧬 #LCSM

A Comparative Study Between Early Onset Colorectal Cancer and Late Onset Colorectal Cancer Patients (EOrOS)
Istituto Clinico Humanitas, Italy
PI: Antonino Spinelli, MD, PhD

NCT06326879
classic.clinicaltrials.gov/ct2/show/NCT06…

With neoadjuvant tx becoming the standard of care in early stage resectable NSCLC, it is imperative to assess the role of ctDNA levels as surrogate end point and select patients for the most appropriate therapeutic strategies - terrific commentary in JAMA Oncology by Christian Rolfo…

#ELCC24 poster addressing the role of pCR as predictor of EFS benefit for immunotp in early NSCLC, and comparing periop and neoad according to PD-L1 and pCR. Kudos to Antonio Nuccio presenting our work!